Previous studies have demonstrated the potential utility of serum GP73 concentration in the assessment of the disease progression in chronic hepatitis B [4, 5, 8, 12, 13], [14], and our own previous findings have demonstrated that serum GP73 represents a surrogate biomarker of liver fibrosis, regardless of the disease etiology [15]. This evidence concerns the gene GOLM1 and Hepatic fibrosis.